You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Bulk Pharmaceutical API Sources for VERICIGUAT


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for VERICIGUAT

Vendor Vendor Homepage Vendor Sku API Url
A2Z Chemical ⤷  Get Started Free AZB32753 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS025289795 ⤷  Get Started Free
abcr GmbH ⤷  Get Started Free AB459404 ⤷  Get Started Free
AEchem Scientific Corp., USA ⤷  Get Started Free AE043144 ⤷  Get Started Free
ZINC ⤷  Get Started Free ZINC72318626 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Vericiguat

Last updated: August 1, 2025

Introduction

Vericiguat, marketed as an oral soluble guanylate cyclase (sGC) stimulator, has emerged as a significant therapeutic agent in managing chronic heart failure with reduced ejection fraction (HFrEF). Since its approval, sourcing high-quality bulk active pharmaceutical ingredients (APIs) has become essential for pharmaceutical manufacturers to ensure consistent drug quality, regulatory compliance, and supply chain stability. This article provides a comprehensive analysis of global API sources for vericiguat, evaluating key manufacturers, regions, regulatory standing, and strategic considerations relevant to stakeholders.

Overview of Vericiguat API

Vericiguat's chemical name is 4-[(4,6-dimethyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl)oxy]butanoic acid. Its synthesis involves complex organic chemistry, necessitating high purity standards and stringent manufacturing practices. Given its recent entry into the market, API sourcing options are emerging, with several manufacturers establishing or expanding their production capabilities.


Global API Manufacturers and Sources for Vericiguat

1. Domestic and International Pharmaceutical Approved API Producers

Major players have received regulations approval globally, with Key API suppliers primarily located in North America, Europe, and Asia.

  • Perrigo / MilliporeSigma (USA / Europe):
    As a leading API and formulation manufacturer, MilliporeSigma supplies numerous cardiovascular APIs and is actively developing vericiguat's production. Their facilities adhere to Good Manufacturing Practices (GMP), and they possess extensive regulatory approvals, including FDA and EMA accreditation. The company’s strategic position enables reliable supply and consistent quality.

  • CordenPharma (Germany):
    Specializing in complex APIs, CordenPharma offers custom synthesis of niche pharmaceuticals, including cardiovascular agents. They possess expertise in late-stage synthesis, ensuring high purity and stability, vital for vericiguat production. Their GMP-certified facilities and compliance with ICH guidelines make them a preferred partner.

  • Piramal Pharma Solutions (India):
    As a significant supplier in Asia, Piramal has built a robust API manufacturing platform that complies with global standards. Their capacity for high-volume production at competitive costs makes them an attractive source, especially for markets requiring large supply quantities.

  • Hikma Pharmaceuticals (Jordan/UK):
    With manufacturing sites in the Middle East and Europe, Hikma positions itself as a reliable supplier for cardiovascular APIs. Their GMP standards and regional logistics capabilities enhance supply chain resilience.

2. API Producers Focused on GMP, Contract Manufacturing, and Custom Synthesis

  • Lonza (Switzerland):
    Known for its biopharmaceuticals and fine chemicals expertise, Lonza supports contract synthesis for complex APIs. Their process development capabilities ensure supply security for newly approved drugs such as vericiguat.

  • Fresenius Kabi (Germany):
    Focused on cardiovascular and critical care APIs, Fresenius maintains GMP-certified production units that could be adapted for vericiguat synthesis, especially for bulk requirements.

  • Dr. Reddy’s Laboratories (India):
    With robust API manufacturing facilities, Dr. Reddy’s offers cost-effective sourcing options that conform to international regulatory standards. They have extensive experience with cardiovascular APIs.


Regional Focus and Considerations

North America

  • Supply Dynamics:
    The United States remains home to some of the leading API producers, primarily due to regulatory sophistication, technological capabilities, and established supply chains.
    Key Suppliers: MilliporeSigma, Catalent, Ajinomoto.

  • Regulatory Environment:
    Strict FDA oversight ensures high-quality standards, though lead times for approvals and compliance documentation can extend procurement timelines.

Europe

  • Supply Dynamics:
    European manufacturers such as CordenPharma and Lonza benefit from proximity to European markets, facilitating logistics and regulatory alignment with EMA standards.
    Advantages: High manufacturing standards and streamlined approval processes.

Asia

  • Supply Dynamics:
    India and China dominate API manufacturing due to cost-effectiveness and scaling capabilities.
    Key Suppliers: Piramal, Hetero, Wockhardt, Zhejiang Hisun Pharmaceutical.
    Consideration: Regulatory compliance (e.g., US FDA, EMA, MHRA) varies and requires due diligence.

  • Risks::** Regulatory variability, potential quality concerns, and geopolitical issues impact supply chain stability.


Regulatory and Quality Considerations

  • GMP Certification:
    Ensures API production aligns with internationally recognized standards, essential for global markets.

  • Dossier and Documentation:
    Suppliers must provide comprehensive Certificates of Analysis (CoA), manufacturing process details, stability data, and validation reports.

  • Supply Chain Resilience:
    Diversification of sources mitigates risks associated with crop failures, regulatory hurdles, or geopolitical disruptions.


Emerging Sources and Future Directions

As the demand for vericiguat grows, emerging manufacturers are investing in scalable synthesis processes, with some startups exploring innovative catalysis methods to improve yields and purity. Additionally, technological advancements in process chemistry aim to simplify synthesis routes, enabling new entrants to supply high-grade APIs competitively.


Strategic Sourcing Recommendations

  • Due Diligence:
    Conduct comprehensive audits of manufacturing sites, review regulatory compliance statuses, and evaluate quality control protocols.

  • Supplier Agreements:
    Establish long-term contracts with flexible volume commitments to secure supply and negotiate pricing.

  • Supply Chain Monitoring:
    Implement real-time tracking and risk assessments to anticipate disruptions promptly.

  • Regulatory Alignment:
    Prefer suppliers with global certifications and experience with vericiguat-specific regulatory submissions.


Key Challenges in API Sourcing for Vericiguat

  • Complex Synthesis:
    The intricate chemical structure demands advanced manufacturing expertise, limiting some low-cost producers.

  • Regulatory Compliance:
    Achieving and maintaining GMP certification and quality standards across different regions remains critical.

  • Supply Security:
    Market entry of new manufacturers could alter supply dynamics, emphasizing the importance of ongoing supplier evaluation.


Conclusion

Securing high-quality bulk API sources for vericiguat necessitates a strategic approach underpinned by rigorous quality standards, regulatory compliance, and supply chain resilience. Leading global suppliers—ranging from established pharmaceutical giants in North America and Europe to scalable Asian manufacturers—offer a spectrum of options. Organizations must balance cost considerations with quality assurance, leveraging diversified sourcing strategies to mitigate risks associated with production variability and geopolitical factors.


Key Takeaways

  • Global Diversity of Suppliers:
    Major API producers span North America, Europe, and Asia, offering varied options aligned with regulatory standards and cost efficiencies.

  • Regulatory and Quality Assurance Are Paramount:
    Ensuring GMP compliance and thorough documentation guarantees API purity and product consistency.

  • Strategic Sourcing Is Critical:
    Diversifying suppliers and building long-term relationships mitigate risks related to supply disruption or quality issues.

  • Emerging Technologies and Manufacturers:
    Innovations in synthesis techniques and new market entrants will influence future API sourcing landscapes.

  • Supply Chain Resilience Enhances Business Continuity:
    Incorporating multiple sources and monitoring geopolitical dynamics enhances stability for vericiguat manufacturing.


FAQs

1. Which regions dominate vericiguat API manufacturing?
Primarily North America (USA), Europe (Germany, Switzerland), and Asia (India, China), with each offering unique advantages regarding cost, quality, and regulatory compliance.

2. What are the primary challenges in sourcing vericiguat APIs?
Complex synthesis processes, regulatory hurdles, maintaining GMP standards, and ensuring supply chain stability.

3. How does regulatory compliance influence API sourcing decisions?
Suppliers with recognized GMP certifications and extensive regulatory track records reduce compliance risks and streamline product registration.

4. Are there emerging API manufacturers for vericiguat?
Yes, several startups and mid-sized firms are developing capabilities, focusing on innovative synthesis methods to improve efficiency and quality.

5. What criteria should companies consider when selecting a vericiguat API supplier?
GMP certification, regulatory track record, manufacturing capacity, quality control standards, supply stability, and cost-effectiveness.


Sources:

[1] U.S. Food and Drug Administration (FDA). Guidance on API manufacturing standards.
[2] European Medicines Agency (EMA). API quality standards and manufacturer approvals.
[3] International Conference on Harmonisation (ICH). Guidelines for Good Manufacturing Practices.
[4] Company disclosures and publicly available regulatory filings of leading API suppliers.
[5] Market intelligence reports on global pharmaceutical API manufacturing capacity and trends.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.